245 related articles for article (PubMed ID: 32579072)
1. Identification of luteolin -7-glucoside and epicatechin gallate from
Maiti P; Nand M; Joshi T; Ramakrishnan MA; Chandra S
J Biomol Struct Dyn; 2021 Sep; 39(14):5048-5057. PubMed ID: 32579072
[TBL] [Abstract][Full Text] [Related]
2. In silico target specific design of potential quinazoline-based anti-NSCLC agents.
Mohammadnejadi E; Razzaghi-Asl N
J Biomol Struct Dyn; 2023 Dec; 41(20):10725-10736. PubMed ID: 36826424
[TBL] [Abstract][Full Text] [Related]
3. Conformational Insight on WT- and Mutated-EGFR Receptor Activation and Inhibition by Epigallocatechin-3-Gallate: Over a Rational Basis for the Design of Selective Non-Small-Cell Lung Anticancer Agents.
Minnelli C; Laudadio E; Mobbili G; Galeazzi R
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32138321
[TBL] [Abstract][Full Text] [Related]
4. Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance.
Hong Z; Cao X; Li N; Zhang Y; Lan L; Zhou Y; Pan X; Shen L; Yin Z; Luo L
Br J Pharmacol; 2014 Jun; 171(11):2842-53. PubMed ID: 24471765
[TBL] [Abstract][Full Text] [Related]
5. Identification of potential edible spices as EGFR and EGFR mutant T790M/L858R inhibitors by structure-based virtual screening and molecular dynamics.
Ahmad Ansari I; Debnath B; Kar S; Patel HM; Debnath S; Zaki MEA; Pal P
J Biomol Struct Dyn; 2024 Mar; 42(5):2464-2481. PubMed ID: 37349948
[TBL] [Abstract][Full Text] [Related]
6. Discovery of the allosteric inhibitor from actinomyces metabolites to target EGFR
Saini R; Kumari S; Bhatnagar A; Singh A; Mishra A
Sci Rep; 2023 Jun; 13(1):8885. PubMed ID: 37264083
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib derivatives and drug-resistance: A perspective from molecular dynamics simulations.
Ahmadi A; Mohammadnejadi E; Razzaghi-Asl N
Comput Biol Med; 2023 Sep; 163():107204. PubMed ID: 37421739
[TBL] [Abstract][Full Text] [Related]
8. Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S.
Assadollahi V; Rashidieh B; Alasvand M; Abdolahi A; Lopez JA
J Cell Biochem; 2019 Aug; 120(8):13046-13055. PubMed ID: 30916819
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study.
Todsaporn D; Zubenko A; Kartsev V; Aiebchun T; Mahalapbutr P; Petrou A; Geronikaki A; Divaeva L; Chekrisheva V; Yildiz I; Choowongkomon K; Rungrotmongkol T
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049777
[TBL] [Abstract][Full Text] [Related]
10. Discovery of highly potent and selective EGFR
Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
[TBL] [Abstract][Full Text] [Related]
11. Computational identification of new TKI as potential noncovalent reversible EGFR
Abdelmalek D; Smaoui F; Frikha F; Ben Marzoug R; Msalbi D; Souissi A; Aifa MS
J Biomol Struct Dyn; 2024 Jun; 42(9):4870-4887. PubMed ID: 37349947
[TBL] [Abstract][Full Text] [Related]
12. A Mechanistic Study of a Potent and Selective Epidermal Growth Factor Receptor Inhibitor against the L858R/T790M Resistance Mutation.
Akher FB; Farrokhzadeh A; Ravenscroft N; Kuttel MM
Biochemistry; 2019 Oct; 58(41):4246-4259. PubMed ID: 31589411
[TBL] [Abstract][Full Text] [Related]
13. p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor.
Ahmad I; Shaikh M; Surana S; Ghosh A; Patel H
J Biomol Struct Dyn; 2022 Apr; 40(7):3046-3059. PubMed ID: 33174519
[TBL] [Abstract][Full Text] [Related]
14. Molecular dynamic simulations based discovery and development of thiazolidin-4-one derivatives as EGFR inhibitors targeting resistance in non-small cell lung cancer (NSCLC).
Karnik KS; Sarkate AP; Lokwani DK; Tiwari SV; Azad R; Wakte PS
J Biomol Struct Dyn; 2023 Jul; 41(10):4696-4710. PubMed ID: 35532095
[TBL] [Abstract][Full Text] [Related]
15. Molecular Docking, Pharmacokinetic and Molecular Simulation Analysis of Novel Mono-Carbonyl Curcumin Analogs as L858R/T790M/C797S Mutant EGFR Inhibitors.
Bhandari SV; Kuthe PV; Patil SM; Nagras OG; Sarkate AP; Chaudhari SY; Surve SV
Chem Biodivers; 2023 Nov; 20(11):e202301081. PubMed ID: 37793119
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy Drug Response to the L858R-induced Conformational Change of EGFR Activation Loop in Lung Cancer.
Ding X; Liu X; Song X; Yao J
Mol Inform; 2016 Oct; 35(10):529-537. PubMed ID: 27643705
[TBL] [Abstract][Full Text] [Related]
17. Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights.
Suriya U; Mahalapbutr P; Wimonsong W; Yotphan S; Choowongkomon K; Rungrotmongkol T
Molecules; 2022 Dec; 27(24):. PubMed ID: 36558033
[TBL] [Abstract][Full Text] [Related]
18. QSAR modeling, pharmacophore-based virtual screening, and ensemble docking insights into predicting potential epigallocatechin gallate (EGCG) analogs against epidermal growth factor receptor.
Bommu UD; Konidala KK; Pabbaraju N; Yeguvapalli S
J Recept Signal Transduct Res; 2019 Feb; 39(1):18-27. PubMed ID: 31223050
[TBL] [Abstract][Full Text] [Related]
19. Psorachromene induces apoptosis and suppresses tumor growth in NSCLC cells harboring EGFR L858R/T790M/C797S.
Wang TH; Leu YL; Chen CC; Li HJ; Yang SC; Huang KY; Chen CY
Phytother Res; 2022 May; 36(5):2116-2126. PubMed ID: 35229911
[TBL] [Abstract][Full Text] [Related]
20.
Patel HM; Ahmad I; Pawara R; Shaikh M; Surana S
J Biomol Struct Dyn; 2021 Mar; 39(4):1491-1505. PubMed ID: 32102624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
